Tumor-bowel fistula: what radiologists should know

被引:18
作者
Tirumani, Sree Harsha [1 ,2 ]
Baez, Juan C. [2 ]
Jagannathan, Jyothi P. [1 ,2 ]
Shinagare, Atul B. [2 ]
Ramaiya, Nikhil H. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA
来源
ABDOMINAL IMAGING | 2013年 / 38卷 / 05期
关键词
Tumor-bowel fistula; Fistula; Molecular targeted therapies; CT; OF-THE-LITERATURE; GASTROINTESTINAL FISTULAS; PNEUMATOSIS-INTESTINALIS; OVARIAN-CARCINOMA; COLORECTAL-CANCER; TARGETED THERAPY; CERVICAL-CANCER; SIGMOID COLON; PERFORATION; BEVACIZUMAB;
D O I
10.1007/s00261-013-9987-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Tumor-bowel fistula is an under reported complication of abdomino-pelvic malignancies which may occur spontaneously due to tumor growth or can be associated with cancer treatment. Chemotherapy and radiotherapy are commonly responsible for tumor-bowel fistulas. Molecular targeted therapies are a new class of drugs that can cause tumor fistulization due to their antiangiogenic properties. Clinically, the fistula can be asymptomatic or can result in devastating complications. Imaging helps in the prompt detection of these fistulas and the complications associated with them. Management of tumor-bowel fistula is individualized but often involves discontinuation of the associated treatment. Radiologists should promptly alert the oncology team about the presence of tumor-bowel fistula and any risk factors for its occurrence like pneumatosis or large metastatic deposits close to bowel loops.
引用
收藏
页码:1014 / 1023
页数:10
相关论文
共 24 条
[1]   Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers [J].
Abu-Hejleh, Taher ;
Mezhir, James J. ;
Goodheart, Michael J. ;
Halfdanarson, Thorvardur R. .
CURRENT ONCOLOGY REPORTS, 2012, 14 (04) :277-284
[2]   Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity [J].
Asmis, Timothy R. ;
Chung, Ki Y. ;
Teitcher, Jerrold B. ;
Kelsen, David P. ;
Shah, Manish A. .
INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) :95-96
[3]   Management of bevacizumab-associated bowel perforation: a case series and review of the literature [J].
Badgwell, B. D. ;
Camp, E. R. ;
Feig, B. ;
Wolff, R. A. ;
Eng, C. ;
Ellis, L. M. ;
Cormier, J. N. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :577-582
[4]   Perforation of a malignant ovarian tumor into the recto-sigmoid colon [J].
Bats, Anne-Sophie ;
Rockall, Andrea G. ;
Singh, Naveena ;
Reznek, Rodney H. ;
Jeyarajah, Arjun .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2010, 89 (10) :1362-1363
[5]   Can We Predict Vesicovaginal or Rectovaginal Fistula Formation in Patients With Stage IVA Cervical Cancer? [J].
Biewenga, Petra ;
Mutsaerts, Meike A. Q. ;
Stalpers, Lukas J. ;
Buist, Marrije R. ;
Schilthuis, Marten S. ;
van der Velden, Jacobus .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (03) :471-475
[6]   Tumor Fistulization Associated With Targeted Therapy: Computed Tomographic Findings and Clinical Consequences [J].
Chow, Henry ;
Jung, Adam ;
Talbott, Jason ;
Lin, Amy M. ;
Daud, Adil I. ;
Coakley, Fergus V. .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2011, 35 (01) :86-90
[7]   Jejunocolic Fistula Associated with an Intestinal T Cell Lymphoma [J].
Chun, Han Byul ;
Baek, Ii Hyun ;
Lee, Myung Seok ;
Kim, Jin Bae ;
Shin, Su Rin ;
Kim, Byung Chun ;
Jung, So Young ;
Kim, Jeong Won .
GUT AND LIVER, 2011, 5 (03) :387-390
[8]   Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients [J].
Curley, SA ;
Marra, P ;
Beaty, K ;
Ellis, LM ;
Vauthey, JN ;
Abdalla, EK ;
Scaife, C ;
Raut, C ;
Wolff, R ;
Choi, H ;
Loyer, E ;
Vallone, P ;
Fiore, F ;
Scordino, F ;
De Rosa, V ;
Orlando, R ;
Pignata, S ;
Daniele, B ;
Izzo, F .
ANNALS OF SURGERY, 2004, 239 (04) :450-458
[9]   Management of genital fistulas in patients with cervical cancer [J].
Emmert, C ;
Kohler, U .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1996, 259 (01) :19-24
[10]   Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].
Faivre, S ;
Delbaldo, C ;
Vera, K ;
Robert, C ;
Lozahic, S ;
Lassau, N ;
Bello, C ;
Deprimo, S ;
Brega, A ;
Massimini, G ;
Armand, JP ;
Scigalla, P ;
Raymond, E .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35